bitmap-araris-logo-rgb (002).jpg
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)
September 24, 2024 08:00 ET | Araris Biotech
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
September 15, 2024 03:00 ET | MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
September 08, 2024 19:10 ET | MacroGenics, Inc.
ROCKVILLE, MD, Sept. 08, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
August 06, 2024 16:01 ET | MacroGenics, Inc.
Upcoming poster presentation of protocol-defined TAMARACK Phase 2 mCRPC study data at ESMO in SeptemberReceived $100.0 million in milestones related to Incyte’s advancement of ZYNYZ®...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conference
June 11, 2024 07:45 ET | MacroGenics, Inc.
ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics to Participate in Upcoming Investor Conferences
May 13, 2024 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, May 13, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics-Logo-(transparent-background).png
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
May 03, 2024 07:30 ET | MacroGenics, Inc.
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
OBI Logo.jpg
浩鼎將在 AACR 2024 年會 發表四篇論文
March 18, 2024 05:00 ET | OBI Pharma Inc.
台灣台北電, March 18, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技(4174)旗下自行開發的抗TROP2抗體藥物複合體(ADC)OBI-992,臨床前數據證明,它在多種動物實驗模式均顯示高效的抗腫瘤活性、優異的藥物動力學表現,和良好的安全性,具有發展為同類最佳抗TROP2...
OBI Logo.jpg
浩鼎将在 AACR 2024 年会   发表四篇论文
March 18, 2024 05:00 ET | OBI Pharma Inc.
台湾台北电, March 18, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技(4174)旗下自行开发的抗TROP2抗体药物复合体(ADC)OBI-992,临床前数据证明,它在多种动物实验模式均显示高效的抗 肿瘤活性、优异的药物动力学表现,和良好的安全性,具有发展为同类最佳抗TROP2 ADC的潜力。...
OBI Logo.jpg
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
March 18, 2024 05:00 ET | OBI Pharma Inc.
TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC)....